Title: Inhaled nitric oxide use in COVID19-induced hypoxemic respiratory failure.

Author names and affiliations.

Abhishek R. Giri Mayo Clinic, Jacksonville, Florida.

Siva Naga S. Yarrarapu Mayo Clinic, Jacksonville, Florida.

Nirmaljot Kaur Mayo Clinic, Jacksonville, Florida.

Alex Hochwald Mayo Clinic, Jacksonville, Florida.

Julie Crook Mayo Clinic, Jacksonville, Florida.

Scott Helgeson Mayo Clinic, Jacksonville, Florida.

Michael F. Harrison Mayo Clinic, Jacksonville, Florida.

Neal Patel Mayo Clinic, Jacksonville, Florida.

Pramod K. Guru Mayo Clinic, Jacksonville, Florida.

Philip Lowman Mayo Clinic, Jacksonville, Florida.

Pablo Moreno-Franco Mayo Clinic, Jacksonville, Florida.

Augustine Lee Mayo Clinic, Jacksonville, Florida.

Devang K. Sanghavi Mayo Clinic, Jacksonville, Florida.

Corresponding author:

Dr. Devang K. Sanghavi Mayo Clinic, Jacksonville, Florida.

sanghavi.devang@mayo.edu

Present Address:

Mayo Clinic

4500 San Pablo Rd S

Jacksonville, Florida

32224

Declaration of interest

Abhishek R. Giri – Declaration of interest: none.

Siva Naga S. Yarrarapu - Declaration of interest: none.

Nirmaljit Kaur - Declaration of interest: none.

Alex Hochwald - Declaration of interest: none.

Julie Crook - Declaration of interest: none.

Scott Helgeson - Declaration of interest: none.

Michael F. Harrison - Declaration of interest: none.

Neal Patel - Declaration of interest: none.

Pramod K. Guru - Declaration of interest: none.

Philip Lowman - Declaration of interest: none.

Pablo Moreno-Franco - Declaration of interest: none.

Augustine Lee - Declaration of interest: none.

Devang K. Sanghavi - Declaration of interest: none.

Highlights:

1. Inhaled nitric oxide can be used in the treatment COVID 19 induced hypoxemic respiratory failure.
2. Inhaled nitric oxide use can lower the burden on overwhelmed medical system.
3. Inhaled nitric oxide use may lower the need for intubation and subsequent invasive mechanical ventilation.

Abstract

Introduction: Nitric Oxide (NO) is an endogenous vasodilator that is synthesized by the vascular endothelium. Due to its vasodilatory effect and short half-life, the use of NO as an exogenous inhaled medication (iNO) to target the pulmonary vasculature, in conditions with increased pulmonary vascular resistance, has been studied.

The use of iNO in patients with ARDS secondary to COVID-19 has therapeutic importance in improving oxygenation. It also has potential anti-viral, anti-inflammatory, and anti-thrombotic properties.

Herein, we want to share our experience of use of iNO in hypoxemic respiratory failure secondary to COVID 19 pneumonia. We hypothesized that iNO may be beneficial at preventing intubation, decreasing invasive mechanical ventilation duration, and consequently improve outcomes including hospital mortality.

Methods: This is a descriptive hypothesis generating study of patients admitted for COVID-19 pneumonia who received iNO for hypoxemic respiratory failure, at a single tertiary care center. We collected information on patient demographics, co-morbidities, iNO treatment, need for intubation, arterial blood gas analysis, laboratory values, hospital length of stay, and mortality. Patients were divided into two groups based on the timing of iNO administration: group 1 - “pre-intubation” (i.e. iNO started at least 1 day prior to endotracheal intubation, if any) and group 2 - “post-intubation” (i.e. iNO started on the same day as or after endotracheal intubation and mechanical ventilation).

Result: A total of 45 (group 1, n=26 [57.8%] vs group2, n=19 [42.2%]) COVID 19 patients who had iNO use. The mean time from hospital admission to iNO administration(days) in group 1 was 2.1 (± 1.8) vs 4.2 (± 5.9) in group 2. The mean hospital length of stay from the beginning of iNO treatment until discharge or death was 18.3 vs 26.2 days, with 8 deaths (30.8%) vs 9 deaths (47.4%) in group 1 vs group 2, respectively.

Discussion:

Our study is unable to demonstrate comparably outcomes benefit of iNO. Although there was a trend towards decreased need for invasive mechanical ventilation in group 1[Only 11 (42.3 %) patients were intubated out of 26 who received iNO early after hospital admission (2.3 days)], no statistical significance could be achieved because of small sample size.

Our study demonstrated that iNO administration pre-intubation did not appear harmful and appears to be safe, complementary to HFNC, signalling the domain where systematic investigation is required to confirm or not the potential for iNO to improve patient outcomes in the management of COVID 19-induced hypoxemic respiratory failure.

Conclusion:

This study showcases the potential benefit of early pre-intubation use of iNO in COVID patients with hypoxemic respiratory failure. This study could conclusively form the basis for a prospective trial and could have a tremendous impact in improving patient outcomes.

Keywords: Inhaled nitric oxide; Acute respiratory distress syndrome; COVID 19; Critical care; Invasive mechanical ventilation

Abbreviations: iNO (Inhaled nitric oxide); ICU (Intensive care unit); SOFA (Sequential Organ Failure Assessment); SD (Standard Deviation).

Main Manuscript:

Introduction:

Nitric oxide (NO) is a potent vasodilator that is endogenously synthesized by the vascular endothelium. Due to its short half-life, inhaled NO (iNO) can provide vasodilation preferentially to ventilated areas improving ventilation-perfusion matching, in addition to potential benefits on pulmonary pressures and right heart afterload reduction.¹

In critically ill patients, management of acute respiratory distress syndrome (ARDS) is predominantly supportive and without specific definitive treatment. The use of iNO in ARDS been relegated to “rescue” or “bridging” therapy for refractory hypoxemia. Although clinical trials have not been able to demonstrate a survival benefit of iNO in ARDS, iNO was universally applied late in the course of hypoxic respiratory failure, specifically, after they had required invasive mechanical ventilation. Early during the COVID-19 pandemic, facing scarce

resources including mechanical ventilators and appropriately trained staff, our center initiated a treatment protocol of considering earlier use of iNO, pre-intubation, to manage refractory hypoxia and possibly delay need for endotracheal intubation or shorten duration of mechanical ventilator need. iNO has been shown to improve gas-exchange in a subset of patients affected by COVID-19 ARDS^{2,3}, but it also has theoretical benefits in the specific context of COVID-19 pneumonia due to its anti-viral, anti-inflammatory, and anti-thrombotic properties.¹

Hence, we aimed to explore whether pre-intubation administration of iNO resulted in any improved clinical outcomes among patients with COVID-19 induced hypoxic respiratory failure. Herein, we want to share our experience of use of iNO in hypoxemic respiratory failure secondary to COVID 19 pneumonia. We hypothesized that iNO may be beneficial at preventing intubation, decreasing invasive mechanical ventilation duration, and consequently improve outcomes including hospital mortality.

Methods:

This is a descriptive hypothesis generating study of patients admitted during June 2020 to December 2020 with COVID-19 pneumonia who received iNO for hypoxemic respiratory failure, at a single tertiary care center. Criteria for iNO (5-20 ppm) addition to high flow nasal canula (HFNC) included patients with pure hypoxemia without increased work of breathing or respiratory acidosis, or if patient showed evidence of pulmonary hypertension (PH) and right ventricular (RV) failure. We collected information on patient demographics, co-morbidities, iNO treatment, need for intubation, arterial blood gas analysis, laboratory values, hospital length of stay, and mortality. Patients were divided into two groups based on the timing of iNO administration: group 1 - “pre-intubation” (i.e. iNO started at least 1 day prior to endotracheal intubation, if any) and group 2 - “post-intubation” (i.e. iNO started on the same day as or after

endotracheal intubation and mechanical ventilation). Moreover, we compared two groups who required invasive endotracheal intubation (group 1) versus those who did not require intubation (group 2) as shown in table 3. We further analysed data based on survival at discharge and divided cohort into two groups: group 1 - alive and group 2 - deceased (refer table 4).

Results:

A total of 45 (group 1, n=26 [57.8%] vs group2, n=19 [42.2%]) COVID19 patients who had iNO use. Age and gender were similar between groups. (refer Table 1)

Variable – Mean (SD) or (Count, %)	iNO before Intubation (N=26)	iNO after Intubation (N=19)	Total (N=45)	p-value
Sex (Female)	9 (34.6%)	7 (36.8%)	16 (35.6%)	1.000
Age in years	66.3 (10.7)	63.7 (14.3)	65.2 (12.2)	0.512
Race				
• White	17 (65.4%)	12 (63.2%)	29 (64.4%)	0.743
• African American	5 (19.2%)	4 (21.1%)	9 (20.0%)	
• Asian	2 (7.7%)	2 (10.5%)	4 (8.9%)	
• Hispanic	2 (7.7%)	0 (0.0%)	2 (4.4%)	
• Pacific Islander	0 (0.0%)	1 (5.3%)	1 (2.2%)	

SOFA score within 24 hours of hospitalization	2.8 (1.5)	6.3 (2.9)	4.3 (2.8)	<0.001
ROX index within 24 hours of hospitalization	5.7 (3.5)	4.0 (1.9)	5.0 (3.0)	0.063
Smoking status ¹				0.384
• Current smoker	1 (3.8%),	1 (5.3%),	2 (4.4%),	
• Former smoker	7 (26.9%),	2 (10.5%),	9 (20.0%),	
• Never smoked	18 (69.2%)	15 (78.9%)	33 (73.3%)	
APACHE II score at the time of iNO administration	11.7 (4.1)	22.4 (7.5)	16.2 (7.8)	<0.001
Time between admission to iNO treatment initiation (days)	2.1 (1.8)	4.2 (5.9)	3.0 (4.2)	0.815

Table 1: Demographic variables by intubation relative to iNO

ROX index – Predicts high flow nasal canula (HFNC) failure/need for intubation.

The mean time from hospital admission to iNO administration(days) in group 1 was 2.1 (±1.8) vs 4.2 (±5.9) in group 2. Severity of illness at admission as indicated by the mean Sequential Organ Failure Assessment (SOFA) score which predicts ICU mortality based on lab results and clinical data, and the APACHE-II scores were worse in group 2 than in group1. The mean ventilator-free days (VFD) was 4.3 in group 1 as opposed to 6.4 in group 2, although this was not statistically different. The mean duration of mechanical ventilation was 12.6 vs 19.1 days in group 1 vs group 2, respectively. The mean hospital length of stay

from the beginning of iNO treatment until discharge or death was 18.3 vs 26.2 days, with 8 deaths (30.8%) vs 9 deaths (47.4%) in group 1 vs group 2, respectively (refer Table 2.).

Variable - Mean (SD) or (Count, %)	iNO before Intubation (N=26)	iNO after intubation (N=19)	Total (N=45)	p-value
Patient intubated at any time (Yes)	11 (42.3%)	19 (100.0%)	30 (66.7%)	<0.001
Total duration of invasive mechanical ventilation (days)	12.6 (9.7)	19.1 (19.0)	16.7 (16.3)	0.605
Ventilator- free days	4.3 (9.6)	6.4 (9.9)	5.6 (9.7)	0.562
Total length of hospital stays (days)	20.4 (13.3)	30.4 (24.6)	24.6 (19.3)	0.29
Length of hospital stay after iNO treatment initiation (days)	18.3 (12.7)	26.2 (23.6)	21.6 (18.3)	0.427
Vital status at discharge (deceased)	8 (30.8%)	9 (47.4%)	17 (37.8%)	0.353

Table 2: Outcome factors by intubation relative to iNO

Ventilator-free days = 28 – x, if successfully liberated from ventilation x days after initiation.
VFDs = 0 if subject dies within 28 days of mechanical ventilation.

In table 3, we compared two groups, group 1(required invasive endotracheal intubation) and group 2 (did not require intubation). High SOFA score at the time of admission associated with increased need for intubation during hospitalization.

Variable - Mean (SD) or (Count, %)	No intubation at any time (N=15)	Patient intubated (N=30)	Total (N=45)	p-value
Sex (Female)	6 (40.0%)	10 (33.3%)	6 (40.0%)	0.746
Age in years	64.1 (11.2)	65.8 (12.9)	65.2 (12.2)	0.736
Race				0.406
• White	3 (20.0%)	6 (20.0%)	9 (20.0%)	
• African American	1 (6.7%)	3 (10.0%)	4 (8.9%)	
• Asian	2 (13.3%)	0 (0.0%)	2 (4.4%)	
	0 (0.0%)	1 (3.3%)	1 (2.2%)	
• Hispanic	9 (60.0%)	20 (66.7%)	29 (64.4%)	
• Pacific Islander				
SOFA score within 24 hours of hospitalization	2.6 (1.4)	5.1 (3.0)	4.3 (2.8)	0.003
APACHE II score at the time of iNO administration	9.9 (3.2)	19.3 (7.6)	16.2 (7.8)	<0.001

Time between admission to iNO treatment beginning (days)	2.3 (2.2)	3.3 (4.9)	3.0 (4.2)	0.873
Total duration of invasive mechanical ventilation (days)		16.7 (16.3)	16.7 (16.3)	
Ventilation free days		5.6 (9.7)	5.6 (9.7)	
Total length of hospital stays (days)	16.5 (12.1)	28.7 (21.1)	24.6 (19.3)	0.030
Length of hospital stay after iNO treatment began (days)	14.2 (10.7)	25.4 (20.3)	21.6 (18.3)	0.031
Patient's vital status at discharge (Deceased)	0 (0.0%)	17 (56.7%)	17 (37.8%)	<0.001

Table 3: Demographic variables and outcome factors by intubation status

In table 4, we compared two groups by their survival at discharge, group 1 (alive) vs group 2 (deceased). In group 1, 13 (46.4%) patients were intubated in comparison to 17 (100%) patients in group 2. Even though numerical values showed correlation to improved survival with decreased time between admission to iNO administration, statistically it is not significant.

Variable - Mean (SD) or (Count, %)	Alive at discharge (N=28)	Deceased (N=17)	Total (N=45)	p-value
Sex (Female)	12 (42.9%)	4 (23.5%)	16 (35.6%)	0.219
Age in years	61.2 (12.5)	71.8 (8.7)	65.2 (12.2)	0.006
Race				0.097
• White	14 (50.0%),	15 (88.2%),	29 (64.4%),	
• African American	8 (28.6%),	1 (5.9%),	9 (20.0%),	
• Asian	3 (10.7%),	1 (5.9%),	4 (8.9%),	
• Hispanic	2 (7.1%),	0 (0.0%),	2 (4.4%),	
• Pacific Islander	1 (3.6%)	0 (0.0%)	1 (2.2%)	
SOFA score within 24 hours of hospitalization	3.8 (2.6)	5.1 (3.0)	4.3 (2.8)	0.114
APACHE II score at the time of iNO administration	13.5 (6.0)	20.5 (8.7)	16.2 (7.8)	0.006
Time between admission to iNO treatment beginning (days)	2.9 (4.3)	3.2 (4.0)	3.0 (4.2)	0.784
Intubation Status (Ventilated)	13 (46.4%)	17 (100.0%)	30 (66.7%)	<0.001
Total duration of invasive mechanical ventilation (days)	21.3 (19.7)	13.2 (12.7)	16.7 (16.3)	0.63

Length of hospital stay after iNO treatment began (days)	25.1 (20.6)	15.9 (12.4)	21.6 (18.3)	0.246
Total length of hospital stays (days)	28.0 (21.4)	19.1 (14.2)	24.6 (19.3)	0.302

Table 4: Demographic variables and outcome factors by death status.

Kaplan Meier curve below estimates that iNO administration delays intubation by about 7 days. The log-rank statistic is $p = 0.0447$.

Figure 1. Kaplan Meier curve showing effects of iNO use on intubation.

Discussion:

In this study, we have summarized the available data and underlined the hypoxemic respiratory failure scenario wherein iNO can be used. Although our study was unable to demonstrate comparably the outcomes of iNO use in either group, across the three different analyses of COVID-19 patients, there was a trend of decreased need for invasive mechanical ventilation in group 1. In group 1 only 11 (42.3 %) patients were intubated out of 26 who received iNO early on after hospital admission (2.3 days), [no statistical significance could be achieved because of small sample size]. High mortality (56.7%) was observed in intubated patients (group 2, table 3) irrespective of iNO administration timing (pre-intubation vs post-intubation). Better SOFA (2.6) and APACHE (9.9) scores were associated with in group 1 (refer table 3) resulting in no need for mechanical ventilation. Overall summarising potentially favourable outcomes (decreased mortality) if nitric oxide was administered earlier in patients with less severity.

In recent years, high flow nasal cannula (HFNC) use has been increased prior to intubation in management of hypoxemic respiratory failure. High flow nasal cannula delivers humidified oxygen and it washes out dead space in hypoxemic respiratory failure. It increases CO₂ clearance, decreases respiratory drive, and facilitate effortless breathing with decreased respiratory rate.⁴ In addition to this, Abou-Arab et al. demonstrated an improvement of PaO₂/FiO₂ ratio with iNO use in COVID-19 patients with severe pneumonia.² Improved arterial oxygenation was also shown by Lotz et al. wherein increased partial pressure of oxygen was seen subsequent to iNO administration in COVID-induced ARDS.³ Nitric oxide inhibits COVID 19 virus replication and its attachment to lung ACE2 receptors. Inhaled NO has anti-inflammatory properties reducing inflammatory mediators induced lung injuries. It improves ventilation/perfusion match, decreases pulmonary vascular resistance as well as transfusion of fluid into the alveolar spaces.⁵ Although no response was demonstrated with iNO in a few studies, design of these studies precluded any formal impression of improved outcome with

iNO use.^{6,7} These studies investigated the use of iNO in COVID-19 with mixed results varying from positive outcomes to a lack of any effect, but did not address the effects of iNO use on intubation and subsequent invasive mechanical ventilator support. Our study demonstrated that iNO administration pre-intubation was not harmful and appears to be safe, complementary to HFNC, signalling the domain where systematic investigation is required to confirm the potential for iNO to improve patient outcomes in the management of COVID-19-induced hypoxemic respiratory failure.

Study Limitations:

This is retrospective study with small sample size; hence desired results were not statistically significant. The effects of iNO were not charted in terms of patient outcomes. We collected SOFA score on admission. Therefore, the severity of patient condition may have deteriorated or improved after 24 hrs. Potential confounders include the novel nature of this virus with rapidly changing standards of medical care, which are not included in this study.

Conclusion:

This study showcases the potential benefit of early pre-intubation use of iNO in COVID-19 patients with hypoxemic respiratory failure. This study could conclusively form the basis for a prospective trial and could have a tremendous impact in improving patient outcomes. Thus, more studies are needed in future to evaluate the effects of iNO use in hypoxemic respiratory failure.

Conflicts of interest-

No conflicts of interest.

REFERENCES

1. Fang W, Jiang J, Su L, et al. The role of NO in COVID-19 and potential therapeutic strategies. *Free Radic Biol Med.* 2021;163:153-162. doi:10.1016/j.freeradbiomed.2020.12.008
2. Abou-Arab O, Huette P, Debouvries F, Dupont H, Jounieaux V, Mahjoub Y. Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study. *Crit Care.* 2020;24(1):645. Published 2020 Nov 12. doi:10.1186/s13054-020-03371-x
3. Lotz C, Muellenbach RM, Meybohm P, et al. Effects of inhaled nitric oxide in COVID-19-induced ARDS - Is it worthwhile? *Acta Anaesthesiol Scand.* 2021;65(5):629-632. doi:10.1111/aas.13757
4. Ricard J-D, Roca O, Lemiale V, et al. Use of nasal high flow oxygen during acute respiratory failure. *Intensive Care Med.* 2020;46(12):2238-2247. doi:10.1007/s00134-020-06228-7
5. Kobayashi J, Murata I. Nitric oxide inhalation as an interventional rescue therapy for COVID-19-induced acute respiratory distress syndrome. *Ann Intensive Care.* 2020;10:61. doi:10.1186/s13613-020-00681-9
6. Tavazzi G, Pozzi M, Mongodi S, Dammassa V, Romito G, Mojoli F. Inhaled nitric oxide in patients admitted to intensive care unit with COVID-19 pneumonia. *Crit Care.* 2020;24(1):508. doi:10.1186/s13054-020-03222-9
7. Ferrari M, Santini A, Protti A, et al. Inhaled nitric oxide in mechanically ventilated patients with COVID-19. *J Crit Care.* 2020;60:159-160. doi:10.1016/j.jcrc.2020.08.007